Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus low-dose dexamethasone continuation study after MK-3475-185 in newly diagnosed multiple myeloma
MOH_2017-12-05_002001Phase 3Not yet recruiting
- Sponsor
- ד"ר נעם בנימיני
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by ד"ר נעם בנימיני. Primary endpoint: Progression-free survival. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
lenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-12-05_002001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-05_002001.